Last edition
News about "paroxysmal supraventricular tachycardia"
Milestone Pharmaceuticals Enrolls First Patient in Phase 3 Trial of Etripamil for AFib-RVR
Milestone Pharmaceuticals has begun its Phase 3 ReVeRA-301 trial to evaluate self-administered etripamil nasal spray for acute AFib-RVR, targeting rapid ventricular rate reduction and symptom relief.
Paroxysmal Supraventricular Tachycardia | 24/08/2026 | By News Bureau
3 NODE - 302 data provided by Milestone Pharma
Milestone Pharma presents data from phase 3 NODE-302 study of etripamil to treat paroxysmal supraventricular tachycardia
Paroxysmal Supraventricular Tachycardia | 03/05/2022 | By Sudeep Soparkar | 735
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy